Daiichi Sankyo

Daiichi Sankyo is a global pharmaceutical company with 125 years of scientific expertise and operations in 45 countries. The company employs over 20,000 people and maintains research facilities in 3 countries and production locations in 6 countries. Daiichi Sankyo is committed to creating innovative medicines for patients worldwide.

Source: https://www.daiichisankyo.com/about_us/

edoxabanSavaysa

factor Xa inhibitor

Savaysa (edoxaban) is an oral factor Xa inhibitor from Daiichi Sankyo. By blocking one central step of the clotting cascade it reduces stroke risk in atrial fibrillation and treats deep vein thrombosis and pulmonary embolism after initial injectable therapy.

Blood clotting depends on a chain reaction of proteins, and factor Xa sits at a key point in that chain, helping make thrombin, which builds the clot.

1 medicine explained